Axcelis Technologies

Phase A — Understand the business

Lens 1 · Company Overview

Axcelis designs, manufactures and services ion-implantation equipment for semiconductor fabs — a single, narrow, mission-critical step in chip-making where dopants (arsenic, boron, phosphorus) are ionized, accelerated and fired into the wafer to form transistors. The product line is the Purion family (high-current, high-energy, medium-current) plus the Ovation batch implanters; ASPs run $2.6M–$12.0M per system. Implant is 98.2% of revenue.

The business has two engines with very different economics:

• Systems — lumpy capex sales to a handful of chipmakers; FY2025 $571.0M (was $782.6M in 2024, $883.6M in 2023). This tracks customer capital-investment decisions and is deep in a down-cycle.
• CS&I / Aftermarket (spares, upgrades, used tools, service) — recurring, tied to fab utilization; FY2025 $268.0M (was $235.3M / $247.0M), now 31.9% of revenue vs 23.1% in 2024. This is the shock absorber holding the P&L up while systems fall, and management's stated target model is ~25% of revenue.

End-markets (management's three buckets): power devices (SiC for EV/industrial), general mature (image sensors, analog, mature logic) and memory (DRAM). Notably no leading-edge logic of consequence — Axcelis is a trailing-edge / specialty capital-equipment name, not an AI-compute play today. Q1-2026 system-shipment mix: mature process 68% (power 35% + general mature 33%), DRAM 32%.

Customer structure: sells direct, 83.7% international, Asia-Pacific–dominated. One customer = 11.0% of FY2025 revenue; top-10 = 55.2% (up sharply from 45.9% in 2024); top-10 hit 72.9% in Q1-2026 — concentration is intensifying as the customer base narrows in the downturn. Payment terms are favorable: typically 90% on shipment / 10% on acceptance, or 20–60% pre-shipment deposits — i.e. customers pre-fund inventory, not Axcelis.

The defining fact of this name right now is not in the business — it's the pending all-stock merger with Veeco Instruments (see Lens 8/12). Standalone, this is a ~$839M-revenue, one-segment, cyclical specialty-equipment company in the trough of its cycle.

Lens 2 · Supply Chain

Upstream → Axcelis → end customer, named where the filings name them:

• Upstream inputs / suppliers: Axcelis keeps system assembly + test in-house in Beverly, MA (417,000 sq ft) and South Korea (Asia Operations Center, 38,000 sq ft) — "high degree of expertise and IP". Non-core subsystems are outsourced to "a limited group of suppliers": vacuum systems, wafer-handling, commodity components. The 10-K explicitly flags single/limited-source dependency and long-lead complex components as a margin/delivery risk — but names no individual supplier (a genuine disclosure gap; the chain upstream of Axcelis is opaque). Purchase commitments for inventory/other were $178.0M at 12/31/25, ~$171.0M due in 2026.
• The company: ~3,400 installed systems across 27 countries; 1,465 employees (1,038 N. America / 398 Asia / 79 Europe). "Ship-from-cell" modular build is the operational moat on delivery time.
• Downstream / end customers (the buyers of implant tools): the world's chipmakers. The 10-K names SMIC explicitly (on the US Entity List, but covered by a 2020 licensing policy for mature fabs). Known end-market verticals: SiC power-device makers (EV/industrial — e.g., the named China SiC shipments), DRAM makers (a "major North American memory customer" placed a new high-current order — almost certainly Micron given geography ), image-sensor / analog mature fabs.
• Chokepoint: the single most important node is US export-control policy on China shipments, not a physical supplier. China is routed through a license regime; the Oct-2022 (amended 2023) framework + Dec-2024 ECCN for 300mm implanters can sever specific customers at the stroke of a rule change.

Lens 3 · Competitive Advantages (moats)

• Duopoly structure with one giant. In ion implant Axcelis "mainly competes against Applied Materials" — the two are the only vendors with a full-range implant line. Others: Sumitomo Heavy Industries Ion Technology, Nissin Ion (Japan), Advanced Ion Beam Technology (Taiwan), and Chinese entrants Kingstone Semiconductor and CETC. Top-3 (AMAT + Axcelis + Sumitomo) hold >60% share; Axcelis ~32% globally.
• The real moat is silicon carbide. Axcelis's Purion Power Series is the supplier of choice for SiC power-device implant; third-party estimates put its SiC implant share at 70–80%. SiC needs many more, higher-energy implant steps than silicon — structurally implant-intensive — so Axcelis over-indexes to it. Power devices = 55% of FY2025 system-shipment value. This is a genuine, durable, process-based moat — but it is levered to the one end-market (EV/industrial power) currently in a cyclical down-leg.
• Switching costs / installed base. Once a Purion is qualified into a process flow, it stays; the 3,400-tool installed base feeds a recurring high-margin aftermarket (product GM 47.9% in FY2025, parts/upgrades richer still).
• Bargaining power is asymmetric and weakening. Against AMAT (vastly greater R&D/scale, the 10-K's own framing) Axcelis is the smaller player. Against customers, no customer has a long-term purchase agreement and concentration is rising (top-10 72.9% in Q1-26) — buyers can defer at will, with "limited or no penalties" on cancellation. IP: 169 US + 356 foreign active patents, but "not substantially dependent on any single patent" — the moat is process know-how + SiC qualification, not a patent wall.

Lens 4 · Segments

Axcelis reports one GAAP segment (Note 17). Management disaggregates three ways. All figures (FY) and (Q1):

By type (Systems vs Aftermarket), $M:

Trend: systems down −27% in 2025, aftermarket +14% — the entire mix shift is the cycle hollowing out the capex line while the recurring base grows. Aftermarket hit a quarterly record $82M in Q4-2025. This is decelerating-systems / accelerating-aftermarket — a classic late-downturn signature.

By geography (shipped-to), $M:

Asia-Pacific is the swing factor (−22% in 2025), driven by China, where revenue fell from ~46% to ~32% of quarterly sales. The "by manufacturing location" cut (Note 17) shows US $482.6M / Asia $306.5M / Europe $50.0M of FY2025 revenue.

By end-market (Q1-2026 system shipments): mature 68% (power 35% / general mature incl. image sensors 33%), DRAM/memory 32%. The cause of the trend: power & general-mature customers "moderated the pace of investments," DRAM stepping up.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print)

Two reads matter: Q4-2025 (the headline beat) and Q1-2026 (the more sobering follow-through).

FY2025 (audited, 10-K): Revenue $839.0M (−17.6% YoY) · GAAP gross margin 44.9% (vs 44.7% — held up only on richer aftermarket mix) · operating income $119.3M (−43%, op-margin 14.2% vs 20.7%) · net income $120.2M · diluted EPS $3.80 (vs $6.15 in 2024, $7.43 in 2023). Operating cash flow $118.3M, capex $11.3M → FCF ≈ $107.0M. The earnings base has halved in two years — this is a trough year.

Q4-2025: revenue $238M, non-GAAP diluted EPS $1.49, both above guidance; the beat was "primarily driven by stronger CS&I aftermarket," CS&I a record $82M. Bookings $127.6M in Q4-2025 vs $84.5M in Q4-2024 — a +51% YoY bookings inflection (off a low base).

Q1-2026 (the tell): revenue $199.0M (+3.3% YoY) — but the quality deteriorated sharply. Gross margin collapsed to 40.5% (from 46.1%) on "less favorable system mix" (product GM 43.8% vs 48.3%; services GM −15.5%); operating income $8.0M (from $29.2M); net income $9.2M; diluted EPS $0.30 (from $0.88). G&A spiked to $26.8M (from $17.4M) on merger costs. Annualizing Q1 ≈ $1.20 EPS run-rate — well below the $3.80 FY2025 print.

Guidance (2026): total revenue "relatively flat" vs 2025, 2H-weighted; full-year non-GAAP GM low-to-mid-40%; tax ~15%; <100bps tariff hit; memory (DRAM) growth offsetting power + general-mature declines, memory expected to "accelerate into 2027".

Balance sheet (12/31/25): cash + ST + LT investments = $145.5M + $228.8M + $182.4M ≈ $556.7M; zero bank debt (only a $42.3M HQ sale-leaseback finance lease); total equity $1,034.7M; working capital $745.5M. Flag: inventories rose to $329.0M (from $282.2M, +16.6%) while revenue fell 17.6% — inventory building into a downturn (see Lens 10). Backlog (incl. deferred systems rev) fell to $457.0M from $645.8M.

Market reaction: despite the falling earnings base, ACLS has re-rated upward to ~$175 — the tape is pricing the Veeco merger + a memory-2027 recovery, not the trailing P&L.

Lens 6 · Earnings Calls (sentiment trend)

Management tone has shifted from defensive-trough to cautiously-constructive-with-an-asterisk over the last several quarters:

• Recurring phrases now: "aftermarket strength / record CS&I," "memory (DRAM) growth into 2026, accelerating into 2027," "second-half weighted," "Veeco combination," "disciplined cost management."
• What they started saying: AI/HBM and DRAM as the growth vector (a deliberate pivot in narrative toward the AI capex wave they don't yet directly touch); the Purion H6 advanced-logic/AI tool.
• What they stopped emphasizing: the SiC/power super-cycle that drove the 2022-23 bull case — now framed as "moderating," "customers digesting," "utilization coming up [on tools they already own]". That last line is the quiet admission that power-device customers are under-utilizing existing tools — i.e., no near-term re-order.
• Honesty signal: management openly guides flat revenue and low-to-mid-40s GM — they are not over-promising on the standalone. The optimism is loaded onto 2027 and the merger.

Lens 7 · Comps

Peer set = large-cap semicap (the comps the market actually prices ACLS against) + Veeco (the merger partner). Multiples are ``; where not sourced, n/a. Mixed as-of dates — treat as directional.

Read: at ~50x forward, ACLS screens in line with or richer than far-higher-quality, faster-growing, AI-direct names (LRCX/KLAC at ~38-39x fwd, AMAT at ~28-32x). But ACLS's "E" is a trough number falling ~8.7%/yr, while LRCX's grew ~40%. On normalized mid-cycle earnings the multiple looks defensible; on trailing/forward it looks expensive for a no-growth, cyclically-impaired, single-product trailing-edge name. Independent DCF/fair-value screens are jarring: Simply Wall St DCF ~$34, GF Value "overvalued ~106%," consensus PT $115–128 — all well below the ~$175 quote. 5-yr avg ROE: n/a (FY2025 ROE ≈ 120.2/1,034.7 ≈ 11.6% trough; FY2023 ≈ 246.3/864.9 ≈ 28% peak ).

Lens 8 · Stock-Price Catalysts (>5% moves, last ~5y)

Pattern, mostly ``:

• 2022–23 SiC super-cycle → the melt-up. ACLS rode the EV/SiC power boom to highs; the stock then "nearly halved" into 2024 as EV demand and China softened.
• China / export-control headlines — every Commerce Dept rule (Oct-2022, Dec-2024 300mm-implanter ECCN) moves the name; new rules pegged at a $20–50M 2025 revenue hit.
• Sept 30, 2025 — the Veeco merger announcement. The single biggest structural catalyst; ACLS is now a merger-arb-adjacent stock. Stockholder approvals (Axcelis + Veeco) Feb 6, 2026.
• Earnings beats on aftermarket (Q4-2025: +$238M rev, $1.49 EPS) — the stock reacts to aftermarket/CS&I surprises and any DRAM/memory order news (the new N. American high-current order) more than to systems.
• Russell index removal — a non-fundamental ~−5.8% move on passive-ownership reshuffling.
• AI/memory sympathy — the recent ~$175 rally is largely the stock being pulled up by the semicap/AI-capex tape + merger optimism, not its own numbers. What the market actually reacts to for this name: (1) the merger's regulatory clock, (2) China policy, (3) aftermarket/memory order surprises — in that order. Systems revenue itself is now almost a lagging indicator.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Russell J. Low, Ph.D. (55) — CEO since May 2023; joined Axcelis 2016 (EVP Engineering → EVP Global Customer & Engineering Ops). Prior: Veeco (MOCVD/MBE), Varian Semiconductor, and the implant division of Applied Materials. A deep ion-implant/process technologist — operator, not promoter. The merger partner is his former employer (Veeco), which cuts both ways (integration knowledge vs. potential pet-deal bias).
• CFO James G. Coogan (45) — joined Sept 2023 from Kaman (aerospace & defense) CFO; PwC-trained, heavy SEC-reporting/IR background. Brought in just ahead of a transformative deal — a capital-markets/M&A-credentialed CFO, sensible for this chapter.
• Bench: several execs (Blumenstock, Redinbo) carry ASML/Veeco/Varian/AMAT pedigrees — an industry-insider team, low promotional risk.
• Capital allocation: disciplined and shareholder-friendly. $121.1M of buybacks in 2025 (vs $60.5M in 2024) at an avg ~$46–84/share through the year — i.e., they were buying in the $46–80s and the stock is now ~$175, so the 2025 program created value. Buybacks paused during merger pendency (zero in Q1-26; $110M still authorized). No dividend. R&D held up through the downturn ($109.0M, 13.0% of revenue, vs 8.6% in 2023) — protecting the franchise rather than cutting to defend EPS.
• Skin in the game / red flags: insider ownership not sourced from the proxy (Part III incorporated by reference) — n/a, not sourced. Flag: insiders sold ~$5.9M in the last 3 months with no buying, and CEO Low adopted a 10b5-1 "Preset Diversification Program" in Q4-2025 — orderly/pre-planned, but a diversification-out signal at a high price. ROE trough ~11.6% / peak ~28%. No related-party transactions disclosed.
• Archetype: professional-manager / technologist team (not founder-led). Appropriate for a mature, cyclical, soon-to-be-merging equipment company.

Lens 10 · Forensic Red Flags

Forensic pass — income statement, balance sheet, cash flow. All `` unless noted.

• Inventory building into a downturn — the headline flag. Inventories +16.6% to $329.0M while revenue fell 17.6% (FY2025); the cash-flow statement shows a −$42.2M inventory use of cash. DSI is stretching. Mitigants: management took a $3.9M excess-&-obsolete provision in 2025 (a real charge, not a quiet build), customers pre-fund inventory via deposits, and ~$171M of the $178M purchase commitments are 2026-dated. Still — the single most important number to watch; if systems stay weak, write-downs follow.
• Revenue recognition. Multiple-performance-obligation system contracts with deferral; deferred revenue $108.9M (down from $138.2M on lower system prepayments). Standard for the industry; the decline in deferred rev is itself a soft demand tell, not an aggressive-rev-rec flag. No revenue pulled forward.
• Cash flow vs earnings — clean. OCF $118.3M vs net income $120.2M (≈0.98x) — earnings are cash-backed, no accruals divergence. SBC modest at $20.8M (~2.5% of revenue) and non-GAAP is not egregiously flattered by it.
• Receivables — improving. AR fell to $168.5M (from $203.1M), a +$37.4M source of cash — receivables are not outrunning revenue (the benign direction).
• Goodwill/intangibles: none of note today (no recent acquisitions) — but this changes materially post-Veeco: ~$4.4B all-stock deal will create large goodwill/intangibles + purchase-accounting noise; future GAAP will be muddied by amortization and integration charges.
• Tax / contingencies: $16.0M valuation allowance on credit carryforwards; $12.7M unrecognized tax benefits; under IRS audit for FY2023 — routine, immaterial.
• Off-balance-sheet: none. HQ sale-leaseback is on-balance-sheet as a finance lease.

Auditor: Ernst & Young LLP — unqualified opinion + clean ICFR attestation; no material weakness; no changes in/disagreements with accountants.

Regulatory findings (required sub-section):

• SEC Litigation Releases: none naming Axcelis since 2021-06-30.
• SEC AAERs: none.
• 10-K Item 3 (Legal Proceedings): "We are not presently a party to any litigation that we believe might have a material adverse effect".
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB enforcement actions surfaced. The only regulator that matters here is China SAMR antitrust review of the Veeco merger (a deal-approval process, not an enforcement action) — ongoing, see Lens 12/Catalysts.
• Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-30. Clean.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028 EPS)

Built bottom-up from FY2025 actuals + management guidance. Output ``; inputs labelled. (Standalone Axcelis — the Veeco merger, if it closes, makes these moot and resets the entire model; see Lens 12.)

Anchors: FY2025 revenue $839.0M, GAAP EPS $3.80, non-GAAP FY2025 ≈ $4.10s area. 2026 guide: revenue flat, GM low-to-mid-40%, tax ~15%, ~30.7M shares.

• FY2026 (base): revenue ~$840M (flat, per guide); GM ~42% (low-to-mid-40s, mix headwind); opex ~$255M; merger costs depress GAAP. GAAP EPS ≈ $2.40–$3.00. Non-GAAP EPS ≈ $3.20–$3.60 (ex merger costs). Note Q1-26 annualized ~$1.20 GAAP, so the back-half must do heavy lifting to hit even the base — execution risk is real.
• FY2027 (base): memory/DRAM "accelerates" per management; assume systems +15%, aftermarket +6%, GM recovers to ~44% on better mix. Revenue ~$940M; non-GAAP EPS ≈ $4.50–$5.00.
• FY2028 (base): mid-cycle normalization, revenue ~$1.0–1.05B, GM ~45%; non-GAAP EPS ≈ $5.50–$6.00 — i.e., it takes until ~2028 to re-approach the 2024 ($6.15) earnings level. Bull path (sharp SiC re-order + DRAM super-cycle): FY2028 EPS $7–8. Bear path (power stays dead, China shipments curtailed, memory disappoints): FY2026 GAAP ~$2.00, FY2028 stuck ~$4.

Forecast not logged. Per --watchlist rules, the Brier forecast.ts create step is skipped in the breadth loop — and a standalone EPS forecast is genuinely low-conviction here because the Veeco close resets the P&L entirely. Logging an ACLS-standalone EPS line would be scoring the wrong entity. (If/when the merger resolves, re-forecast the combined company.)

Lens 12 · Bull vs Bear

Bull case. Axcelis is a quality, debt-free, cash-generative duopolist with a near-monopoly (70–80%) in SiC implant and a recurring aftermarket now ~32% of revenue and growing through the trough. It is in the bottom of a cycle — power/EV and China will eventually re-order, DRAM/HBM is inflecting now (management sees memory accelerating into 2027), and the Purion H6 extends it toward advanced logic. The merger with Veeco is the re-rating engine: it ~doubles the company, bolts on Veeco's AI-direct exposure (laser annealing for gate-all-around + HBM, advanced packaging, ion-beam) — exactly the secular growth Axcelis lacks — for a ~$4.4B all-stock price, creating a diversified $1.5B-revenue semicap platform with cost synergies and a far better growth narrative. Management bought back $121M of stock in the $46–80s (value-accretive) and protected R&D through the downturn. On normalized mid-cycle EPS ($6) the multiple is reasonable for a consolidated AI-levered equipment name.

Bear case (2–3 ways it permanently impairs / de-rates):

1. The valuation is borrowed, not earned. ~50x forward on a trough, falling earnings base (−8.7%/yr consensus), vs independent DCF/fair-value of ~$34 and consensus PTs of $115–128 — half the ~$175 quote. The stock is pricing Veeco's AI story + a 2027 recovery that hasn't shown up in the standalone P&L. If the merger breaks or memory disappoints, there is enormous air underneath.
2. The deal is hostage to China. The only remaining condition is China SAMR antitrust approval, and as of mid-2026 it has not cleared — put under "simplified procedure" Jan-2026 but ION Analytics flags "closer scrutiny amid possible complaints" and third-party concerns, with SAMR reviewing both the ion-implant market (Axcelis 20-25% share) and Veeco's heat-processing market. China holding a US implant-leader's transformative deal hostage amid a tech-trade war is a live, plausible, asymmetric risk. A blocked/delayed deal (outside date Sept-30-2026, extendable to June-30-2027) collapses the merger-arb premium and leaves a flat, cyclically-depressed pure-play — back toward the consensus $115 or lower.
3. Structural China + concentration erosion. China fell 46%→32% of sales; export controls can curtail it further; domestic Chinese implant champions (Kingstone, CETC) are climbing the curve and will eventually displace Axcelis in mature Chinese fabs. Meanwhile top-10 concentration hit 72.9% — fewer, larger, no-contract customers who can defer at will.

Pre-mortem (18 months out, thesis broke): China SAMR slow-walked or blocked the Veeco deal (or extracted concessions); the merger-arb/AI premium evaporated; standalone power-device demand stayed in digestion through 2026-27; DRAM strength proved a head-fake or got absorbed in-quarter without flowing to backlog; the stock round-tripped from ~$175 to the $90–115 fair-value zone as the market re-anchored on trough earnings × a normal cyclical multiple.

Are multiples too high? On trailing/forward earnings, yes — demonstrably, vs both peers and intrinsic-value screens. The only frame in which ~$175 is defensible is normalized post-merger earnings power, which is unproven and gated on a regulator in Beijing.

Contrarian view (what the market refuses to see): the bulls are treating a binary, China-gated, regulatory event as a near-certainty and pricing the combined AI-platform multiple before the deal is legally done — while the standalone Q1-26 print (GM 40.5%, EPS $0.30) quietly screams that the base business is still deteriorating. The risk/reward is skewed: limited incremental upside if the deal closes on schedule (largely priced), large downside if China balks.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the money-machine: ~98% of revenue is one product category (ion implant) sold to <20 customers, levered to the two end-markets (SiC power, China mature) currently weakest, with no long-term contracts and rising concentration (top-10 = 72.9% in Q1-26). A single large customer deferring (one was 11% of FY25) swings a quarter.
• Revenue concentration shift: China 46%→32% and falling; US export policy can sever specific Chinese customers overnight; Chinese domestic implanters (Kingstone, CETC) are explicitly named as developing competitors who will take the mature Chinese socket Axcelis currently holds. The TAM Axcelis over-indexes to (SiC) is exactly where it is most exposed to a structural China-localization loss.
• Why the moat is weaker than bulls think: against AMAT it is the small player "with substantially greater resources"; the SiC 70-80% share is a cyclical crown that shrinks in absolute dollars when power capex dries up (it has) and is contestable by AMAT's VIISta/Varian line and Chinese entrants over time.
• Most dangerous competitor bulls underestimate: the Chinese domestic implant ecosystem (Kingstone/CETC) — not on tech today, but on policy-forced localization of mature-node tooling, which is precisely Axcelis's bread and butter.
• Worst capital-allocation/incentive flags: none egregious — but the merger is the CEO's former employer (Veeco), insiders are net sellers (~$5.9M, no buys), and the CEO adopted a diversification 10b5-1 plan at a high price.
• What must hold for ~$175: (a) China SAMR approves Veeco on schedule, (b) the combined company delivers AI/HBM synergy growth, (c) memory accelerates into 2027 as guided, (d) power/SiC eventually re-orders. Remove any one and the trough-earnings × ~50x math falls apart.
• If growth disappoints 20–30%: on a flat-to-down standalone base, a 25% miss → GAAP EPS toward ~$1.50–2.00; at even a generous 25x that's ~$40–50/share — which is why the DCF screens print $34. The downside to fair value is roughly −35% to −50% from ~$175.
• Single scenario that permanently impairs: China formally blocks the Veeco merger (or makes it commercially unviable) and uses it as cover to accelerate localization away from Axcelis in Chinese mature fabs — simultaneously killing the re-rating catalyst and structurally shrinking the largest end-market. Plausibility: moderate, not negligible, given the geopolitical backdrop.

Lens 14 · Management Questions (ordered by information value)

1. China SAMR: what is your current, specific read on the timeline and conditionality of SAMR approval — are remedies/divestitures on the table, and what is your true outside-date contingency if it slips past mid-2027?
2. If the Veeco merger does not close, what is the standalone capital-allocation and strategy plan — resume buybacks at ~$175, or is the stock then overvalued on your own numbers?
3. Walk me through the 2027 memory/DRAM "acceleration" in units and dollars — how much is contracted/visible vs. hoped-for, given memory books-and-ships in-quarter and doesn't sit in backlog?
4. Power/SiC: what utilization level at your power-device customers triggers a re-order cycle, where are they now, and how much of the 70-80% SiC share is defensible against AMAT and Chinese entrants over 3 years?
5. Inventory rose 16.6% into an 18% revenue decline — what gives you confidence the $329M is good inventory, and what's the write-down risk if systems stay weak through 2026?
6. Post-merger, what is the pro-forma revenue, gross-margin and EPS bridge, and how much goodwill/intangible amortization will GAAP carry?
7. Quantify the realistic cost and revenue synergies with Veeco, the timeline, and the integration risk given two different technology stacks.
8. What is your China revenue-floor assumption under a further tightening of US export controls — model the downside case.
9. Customer concentration hit 72.9% (top-10) — how do you de-risk dependence on so few, no-contract buyers?
10. Where are you on advanced logic (Purion H6) — real design-ins and revenue, or aspiration? Who are the customers?
11. Japan (METI funding, Rapidus, TSMC Kumamoto) — what is the concrete revenue opportunity and your share of it?
12. Aftermarket is now ~32% of revenue and the earnings cushion — what is the sustainable through-cycle ceiling, and how do you defend it against third-party parts/service providers?
13. Services gross margin went negative (−15.5% in Q1-26) — is that a one-off mix issue or a structural problem in the service contract book?
14. How should investors think about your normalized mid-cycle earnings power (the number that justifies the multiple), and what year do you actually reach it?
15. Insiders are net sellers and you adopted a 10b5-1 diversification plan — what should shareholders infer about your own view of intrinsic value at current prices?

---